Skip to main navigation

Contact Us

Investor Relations

Our Company
Product Candidates
- Pipeline
- MultiTAA Therapies
Our Science
Clinical Trials
- Active Clinical Trials
- Expanded Access Policy
Investors/Media
Careers

Investors/Media

Press Releases

Press Releases

Year

Jan 19, 2022

Marker Therapeutics Receives FDA Orphan Drug Designation for its Multi-Antigen Targeted T Cell Therapy for Pancreatic Cancer

Dec 09, 2021

Marker Therapeutics Appoints Biotech Executive Katharine Knobil, M.D., to Board of Directors

Nov 18, 2021

Marker Therapeutics Announces that Data from Investigator-Sponsored Phase 1 Study With its MultiTAA-Specific T Cells to be Presented at the 2021 American Society of Hematology Annual Meeting

Nov 10, 2021

Marker Therapeutics Reports Third Quarter 2021 Operating and Financial Results

Sep 07, 2021

Marker Therapeutics to Present at Three Upcoming September Investor Conferences

Aug 19, 2021

Marker Therapeutics Awarded $13.1 Million Grant from the Cancer Prevention and Research Institute of Texas

Aug 10, 2021

Marker Therapeutics Reports Second Quarter 2021 Operating and Financial Results

Jul 28, 2021

Marker Therapeutics Announces Opening of New cGMP Manufacturing Facility

Jul 06, 2021

Marker Therapeutics Announces Completion of Safety Lead-In Portion of Phase 2 Study in Post-Transplant AML

Jun 16, 2021

Marker Therapeutics to Present at the Virtual Raymond James Human Health Innovation Conference

Pagination

First page
Previous page
…
Page 3
Page 4
Page 5
Page 6
Current page 7
Page 8
Page 9
Page 10
Page 11
…
Next page
Last page

Displaying 61 - 70 of 126

Investors/Media

Investors/Media Home
News & Events
- Press Releases
- Events & Presentations
Stock Information
Financials & Filings
Corporate Governance
Investor Resources

IR and Media Contacts

investor.relations@markertherapeutics.com
(713) 400-6400

©2026 Marker Therapeutics, Inc. All Rights Reserved.

Footer Links

Sitemap
Terms of Use
Privacy Policy